Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate
MWN-AI** Summary
Windtree Therapeutics, Inc. has made significant strides in strengthening its patent estate for istaroxime and next-generation SERCA2a activators, essential therapies aimed at addressing acute heart failure (HF). On November 14, 2025, the company announced the allowance of patents for istaroxime in Canada and Mexico, and a newly granted patent for a pure SERCA2a activator in Israel. This expands Windtree's patent arsenal to a total of 59 issued or allowed patents, alongside 17 pending applications.
Istaroxime, a dual-mechanism therapy, aims to improve both systolic and diastolic cardiac function without the common side effects associated with traditional treatment options, such as arrhythmias and renal function impairment. It targets significant health challenges associated with acute heart failure—a condition that affects 60 million people worldwide, with around 1.5 million cases in the U.S. alone—by enhancing myocardial contractility while also promoting relaxation.
Windtree’s Chief Executive Officer, Jed Latkin, expressed confidence in the unique profile of istaroxime, particularly its potential to serve patients with low blood pressure, who represent a critical demographic needing effective treatment. The company's encouraging preclinical and Phase 2 clinical data further support the advancement towards potential Phase 3 studies.
The innovative research from Windtree reflects its commitment to developing therapies that could fill substantial gaps in existing cardiovascular treatment options. As the company seeks partnerships for ongoing development, its advancements highlight a promising future in heart failure management and potential for generating revenue through its diversified therapeutic pipeline.
MWN-AI** Analysis
Windtree Therapeutics (OTCID: WINT) has recently announced significant advancements in its patent portfolio for Istaroxime and its next-generation SERCA2a activators, enhancing its position in the competitive landscape of heart failure treatments. With 59 patents issued or allowed and 17 pending, the company is well-positioned for future growth, particularly as it awaits potential partnerships to further develop its promising assets.
The newly allowed patents in Canada and Mexico for acute heart failure not only validate Windtree’s innovative approach but also open doors to new markets. Given the urgency for more effective treatments—especially since acute heart failure affects millions globally—Windtree’s focus on developing Istaroxime, which has shown positive results in renal function and a lower incidence of arrhythmias than current therapies, may cater to a critical need in the healthcare market.
Investors should closely monitor Windtree's strategic moves, particularly regarding its intent to pursue partnerships that could expedite the advancement of Istaroxime into Phase 3 clinical trials. The favorable outcomes from previous studies indicate a strong potential for success in a field where alternatives are limited and often carry significant side effects.
With heart failure admissions increasing, and the current therapeutic landscape lacking in innovative solutions, Windtree’s investment in its patent estate is timely. Companies with robust intellectual property protections usually enjoy a competitive edge, enabling sustained revenue generation through partnerships and licensing agreements down the line.
For investors, Windtree represents a speculative yet intriguing opportunity in the biopharmaceutical space—recognizing both its potential upside with Istaroxime and the inherent risk associated with clinical development phases. Maintaining a keen eye on upcoming developments and assessing any potential partnership announcements will be key to evaluating Windtree's market proposition going forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Windtree has a total of 59 issued or allowed patents and 17 pending patents for Istaroxime and its SERCA2a activators
Windtree received recent notification of allowed Istaroxime patents
for acute heart failure in Canada and Mexico
The pure SERCA2a activators patent for acute heart failure was granted in Isreal
WARRINGTON, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating company, announced that acute heart failure patents are allowed in Canada (Patent Application No. 3,130,261) and Mexico (Patent Application No. MX/a/2021/010483). Additionally, the next generation pure SERCA2a activator patent for heart failure was granted in Isreal (Patent Application No. 291412).
This latest news for Windtree’s cardiovascular pipeline makes a total of 58 patents issued or allowed, with 17 pending. The cardiovascular patent estate includes istaroxime, the dual mechanism SERCA2a activators and the pure SERCA2a activators for the treatment of heart failure, prevention of arrhythmias and treatment of cardiogenic shock.
Heart failure affects 60 million people globally of which approximately 20 million are admitted annually due to Acute HF, 1.5 million in the US. In patients with systolic blood pressure BP < 120 mmHg, in-hospital and 6-month mortality can reach double digit percentages. Additionally, hospital readmission after discharge and/or worsening heart failure and/or death are areas that need drug innovation.
Current treatment options for acute heart failure patients are limited and can have side effects such as arrythmias and problems with renal function.
“We are very pleased to be strengthening our cardiovascular patent estate,” said Jed Latkin, Chief Executive Officer of Windtree. “We believe that istaroxime has a unique profile to effectively treat acute heart failure patients with low blood pressure, who are most in need. Further, istaroxime has demonstrated favorable results in renal function and no increase in arrythmias that is lacking with currently available drugs. We are pursuing partnership for development and believe that the clinical studies to date are very encouraging in considering a Phase 3 program for istaroxime.”
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a diversified company with several divisions and focused on becoming a revenue generating company with future profitability.
About Istaroxime
Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously can significantly improve cardiac function and blood pressure without increasing heart rate or the incidence of clinically significant cardiac rhythm disturbances.
About Pure SERCA2a Activators
These compounds activate SERCA2a and Windtree Therapeutic’s research and development program is evaluating these preclinical product candidates, including oral and intravenous SERCA2a activator heart failure compounds.
Forward Looking Statements
The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: risks related to the Company’s ability to begin its environmental services business, and manage costs and execute on its operational and budget plans. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact Information:
Eric Curtis
[email protected]
FAQ**
How does Windtree Therapeutics Inc. WINT plan to leverage its recent patent approvals for Istaroxime in Canada and Mexico to expedite market entry for acute heart failure treatments?
Given the unique profile of Istaroxime in treating acute heart failure patients with low blood pressure, what strategies is Windtree Therapeutics Inc. WINT employing to secure partnerships for further development?
Can Windtree Therapeutics Inc. WINT provide updates on the timeline for advancing Istaroxime into Phase 3 clinical trials, considering its promising results in earlier studies?
What measures is Windtree Therapeutics Inc. WINT taking to mitigate the risks and uncertainties outlined in its forward-looking statements, particularly concerning its operational plans and potential revenue generation?
**MWN-AI FAQ is based on asking OpenAI questions about Windtree Therapeutics Inc. (NASDAQ: WINT).
NASDAQ: WINT
WINT Trading
-12.12% G/L:
$0.116 Last:
1,921,610 Volume:
$0.132 Open:
